Compass Pathways PLC Sponsored ADR $CMPS Holdings Reduced by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. cut its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 11.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 884,903 shares of the company’s stock after selling 109,490 shares during the period. Jefferies Financial Group Inc.’s holdings in Compass Pathways were worth $11,008,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the last quarter. Ancora Advisors LLC bought a new stake in shares of Compass Pathways in the second quarter valued at about $43,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Compass Pathways in the third quarter valued at about $85,000. Finally, Entropy Technologies LP bought a new stake in shares of Compass Pathways in the first quarter valued at about $110,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Up 0.5%

Shares of NASDAQ CMPS opened at $9.30 on Thursday. Compass Pathways PLC Sponsored ADR has a 52-week low of $4.88 and a 52-week high of $15.87. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.50 and a current ratio of 1.50. The business has a fifty day moving average of $12.06 and a two-hundred day moving average of $10.44. The stock has a market cap of $1.32 billion, a PE ratio of -2.66 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. As a group, equities research analysts expect that Compass Pathways PLC Sponsored ADR will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Compass Pathways in a research report on Tuesday, November 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating on shares of Compass Pathways in a research report on Monday. Wells Fargo & Company decreased their price objective on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 4th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and a consensus price target of $23.14.

Recent Compass Pathways Headlines

Here are a few of the latest headlines about CMPS:

• Positive Sentiment: HC Wainwright’s updated estimates project narrower losses: its FY2026 EPS forecast improved to ($1.40) from ($1.58), and its FY2027 forecast to ($1.17) from ($1.56). The firm also raised estimates across the reported quarters through 2027 and maintained its Buy rating. Better-than-previous forecasts may support investor sentiment, though the company is still expected to post losses. Compass Pathways analyst estimates
• Neutral Sentiment: Compass Pathways plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The appearance could provide investor visibility, but the announcement did not disclose new company developments. Conference announcement

About Compass Pathways

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.